| Name | Size | Date | MIME Type |
|---|
| ../ | - | Nov 20, 2025 03:46:16 | Directory |
| 2021 04 17 courrier PELE DAJR_2021042000157 S.pdf | 832.67 KB | Nov 20, 2025 03:46:16 | application/pdf |
| ANNEXES - Abbréviations Line listing_v2.pdf | 273.72 KB | Nov 20, 2025 03:46:16 | application/pdf |
| articles_codes_base_nationale_pharmacovigilance.txt | 0.94 KB | Nov 20, 2025 03:46:16 | text/plain |
| Explication_codes_C_B_S_Méthode française d’imputabilité médicamenteuse, dite méthode Bégaud _ Centre Régional de Pharmacovigilance du Nord-Pas-de-Calais.pdf | 578.14 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_101578_charabianibagheri_haleh_20210315.pdf | 112.39 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_102133_cottin_judith_20210329(3).pdf | 113.64 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_102138_alttebacher_martine_20210329.pdf | 112.53 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_103560_massyguillemant_nathalie_20210429.pdf | 112.83 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_103656_micallefroll_joelle_20210430.pdf | 114.65 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_94736_lepelley_marion_20201102.pdf | 111.70 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_95206_pariente_antoine_20201110.pdf | 117.49 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_95868_gautier_sophie_20201124.pdf | 112.50 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_95955_valnetrabier_marieblanche_20201125.pdf | 111.91 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_95993_lacroix_isabelle_20210429.pdf | 112.76 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_96192_graschampel_valerie_20201201.pdf | 112.03 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_96464_atzenhoffer_marina_20201205.pdf | 112.34 KB | Nov 20, 2025 03:46:16 | application/pdf |
| point_1_signed_declaration_97247_salvo_ciccio_20201221.pdf | 113.70 KB | Nov 20, 2025 03:46:16 | application/pdf |
| points_3_et_4_20210618 - VACCIN ASTRAZENECA - CADA.pdf | 3.63 MB | Nov 20, 2025 03:46:16 | application/pdf |
| points_3_et_4_20210618 - VACCIN COMIRNATY - CADA.pdf | 5.35 MB | Nov 20, 2025 03:46:16 | application/pdf |
| points_3_et_4_20210618 - VACCIN MODERNA - CADA.pdf | 981.96 KB | Nov 20, 2025 03:46:16 | application/pdf |
| points_3_et_4_ASTRAZENECA_CasMarquants_20210624.pdf | 41.90 KB | Nov 20, 2025 03:46:16 | application/pdf |
| points_3_et_4_COMIRNATY_CasMarquants_20210624.pdf | 54.82 KB | Nov 20, 2025 03:46:16 | application/pdf |
| points_3_et_4_MODERNA_CasMarquants_20210624.pdf | 33.58 KB | Nov 20, 2025 03:46:16 | application/pdf |
| reponse_ansm_demande_cada_06082021_recue_09082021_1V152.pdf | 842.21 KB | Nov 20, 2025 03:46:16 | application/pdf |
| resume_Réactualisation de la méthode française d’imputabilité des effets indésirables des médicaments _ Thérapie.pdf | 211.76 KB | Nov 20, 2025 03:46:16 | application/pdf |
| Yannick A et al., Updating the French Method for the Causality Assessment of Adverse Drug Reactions, Therapie 2013_JCEMethodelogistique.pdf | 250.45 KB | Nov 20, 2025 03:46:16 | application/pdf |